Clinical studies of anti-PD-1/PD-L1 antibodies in combination with antiangiogenic drugs have shown good efficacy and manageable safety in the treatment of various solid tumors, recent studies (11) showed the superiority of immunization with anlotinib, specifically cadonilimab (PD-1/CTLA-4 bispeci-c antibody) plus anlotinib, in lung cancer. Here, CD274 is linked to lung cancer.